Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

220.91 +0.05 (+0.02%)
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 121,954
Open 220.66
Bid (Size) 220.89 (100)
Ask (Size) 220.91 (1,800)
Prev. Close 220.86
Today's Range 220.66 - 221.00
52wk Range 15.22 - 221.20
Shares Outstanding 49,506,268
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
Halper Sadeh LLC Encourages EB, KPLT, WBD, CDTX Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm immediately as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+709.2%
+709.2%
1 Month
+0.3%
+0.3%
3 Month
+200.6%
+200.6%
6 Month
+371.6%
+371.6%
1 Year
+844.1%
+844.1%

More News

Read More
Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover ↗
Via Stocktwits
News headline image
Halper Sadeh LLC Encourages CADE, MRSN, CDTX Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Is This Pharmaceutical Giant a Buy After a Major Acquisition? ↗
Via The Motley Fool
Topics Death
News headline image
3 Non-AI Stocks to Buy: MRK, UPS, CVX ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%? ↗
Via The Motley Fool
News headline image
Halper Sadeh LLC Encourages AXTA, SEMR, CDTX Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗
Via The Motley Fool
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Via The Motley Fool
News headline image
Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗
Via MarketBeat
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
Via The Motley Fool
News headline image
Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗
Via Benzinga
News headline image
Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Which stocks are moving on Friday? ↗
Via Chartmill

Frequently Asked Questions

Is Cidara Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cidara Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cidara Therapeutics, Inc. - Common Stock trade on?
Cidara Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cidara Therapeutics, Inc. - Common Stock?
The ticker symbol for Cidara Therapeutics, Inc. - Common Stock is CDTX on the Nasdaq Stock Market
What is the current price of Cidara Therapeutics, Inc. - Common Stock?
The current price of Cidara Therapeutics, Inc. - Common Stock is 220.91
When was Cidara Therapeutics, Inc. - Common Stock last traded?
The last trade of Cidara Therapeutics, Inc. - Common Stock was at 12/24/25 12:59 PM ET
What is the market capitalization of Cidara Therapeutics, Inc. - Common Stock?
The market capitalization of Cidara Therapeutics, Inc. - Common Stock is 10.94B
How many shares of Cidara Therapeutics, Inc. - Common Stock are outstanding?
Cidara Therapeutics, Inc. - Common Stock has 11B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.